National Institutes of Health: Glioma trials

The registry lists 120 Glioma studies with National Institutes of Health as lead sponsor. 4 are open to participants now and 52 have results posted.

Phase 1 65Phase 2 63Phase 3 1No phase 11(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent GlioblastomaRecruitingNCT07416188Phase 1/2
• Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent GlioblastomaRecruitingNCT06344130Phase 1
• PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN AmplificationsRecruitingNCT06161519Phase 1/2
• 000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) MutationsRecruitingNCT05588141Phase 1/2
• Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral MicrodialysisActive, not recruitingNCT05413304Phase 1Results posted
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04320888Phase 2Results posted
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04284774Phase 2Results posted
• Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT04195555Phase 2Results posted
• Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator PhenotypeActive, not recruitingNCT03718767Phase 2Results posted
• Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03698994Phase 2Results posted
• Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS TumorsActive, not recruitingNCT03598244Phase 1Results posted
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03526250Phase 2Results posted
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03233204Phase 2Results posted
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03220035Phase 2Results posted
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213704Phase 2Results posted
• Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213678Phase 2Results posted
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213665Phase 2Results posted
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213652Phase 2Results posted
• Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingNCT03212274Phase 2Results posted
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03210714Phase 2Results posted
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
• Protein Phosphatase 2A Inhibitor, in Recurrent GlioblastomaCompletedNCT03027388Phase 2Results posted
• Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)TerminatedNCT03018288Phase 2Results posted
• Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid TumorsCompletedNCT02780804Phase 1Results posted
• Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine GliomasCompletedNCT01922076Phase 1Results posted
• Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT01648348Phase 1/2Results posted
• Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway GliomaCompletedNCT01553149Phase 2Results posted
• Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine GliomasCompletedNCT01514201Phase 1/2Results posted
• Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or EpendymomaCompletedNCT01462695Phase 2Results posted
• CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIIICompletedNCT01454596Phase 1/2Results posted
• Phase I-II Everolimus and Sorafenib in Recurrent High-Grade GliomasCompletedNCT01434602Phase 1/2Results posted
• Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent GlioblastomaCompletedNCT01266031Phase 1/2Results posted
• Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade GliomaCompletedNCT01236560Phase 2/3Results posted
• Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine GliomaCompletedNCT01189266Phase 1/2Results posted
• RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant GliomaTerminatedNCT01189240Phase 1/2Results posted
• Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT01051557Phase 1/2Results posted
• Sunitinib to Treat Recurrent Brain CancerTerminatedNCT00923117Phase 2Results posted
• Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard TherapyCompletedNCT00679354Phase 2Results posted
• Sunitinib in Treating Patients With Recurrent Malignant GliomasCompletedNCT00499473Phase 2Results posted
• Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2Results posted
• Bevacizumab and Irinotecan to Treat Brain TumorsTerminatedNCT00393094Phase 2Results posted
• Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine GliomaCompletedNCT00387790Phase 2Results posted
• Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade GliomaCompletedNCT00381797Phase 2Results posted
• VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to TemozolomideCompletedNCT00369590Phase 2Results posted
• Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain TumorsCompletedNCT00302159Phase 2Results posted
• O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem TumorsCompletedNCT00275002Phase 2Results posted
• Bevacizumab for Recurrent Malignant GliomaCompletedNCT00271609Phase 2Results posted
• Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant GliomaCompletedNCT00112736Phase 1/2Results posted
• Tamoxifen and Bortezomib to Treat Recurrent Brain TumorsCompletedNCT00108069Phase 2Results posted
• Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System TumorsCompletedNCT00095940Phase 1/2Results posted
• Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem GliomaCompletedNCT00079339Phase 1/2Results posted
• Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent GliomasCompletedNCT00047879Phase 2Results posted
• Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive MeningiomaCompletedNCT00045110Phase 1/2Results posted
• Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed GliomasCompletedNCT00042991Phase 1/2Results posted
• A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine GliomasCompletedNCT00036569Phase 2Results posted
• Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent GliomaTerminatedNCT00021229Phase 1/2Results posted
• Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) TumorsCompletedNCT07374692
• Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following TreatmentActive, not recruitingNCT05859334Phase 2
• A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)SuspendedNCT05099003Phase 1/2
• Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT04817254Phase 2
• Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR SpectroscopySuspendedNCT03952598Phase 2
• Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade GliomaActive, not recruitingNCT03919071Phase 2
• Rare CNS Tumors Outcomes &RiskCompletedNCT03251989
• Natural History of and Specimen Banking for People With Tumors of the Central Nervous SystemCompletedNCT02851706
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System TumorsCompletedNCT02415153Phase 1
• Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or MedulloblastomaActive, not recruitingNCT02359565Phase 1
• Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade GliomaCompletedNCT02101905Phase 1
• High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent GliomaTerminatedNCT01378481Phase 1
• AZD8055 for Adults With Recurrent GliomasCompletedNCT01316809Phase 1
• (11C)dLop as a Marker of P-Glycoprotein Function in Patients With GliomasTerminatedNCT01281982
• RO4929097 in Treating Patients With Recurrent Invasive GliomasTerminatedNCT01269411Phase 1
• Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine GliomasCompletedNCT01222754Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT01119599Phase 1
• A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With GliomasWithdrawnNCT01117155
• Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaTerminatedNCT01088763Phase 1
• Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord TumorsCompletedNCT01076530Phase 1
• Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaCompletedNCT00994500Phase 1
• ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS TumorsCompletedNCT00946335Phase 1
• Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to TreatmentCompletedNCT00929903Phase 1
• An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade GliomaTerminatedNCT00880061Phase 1
• Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant GliomaCompletedNCT00650923Phase 1
• Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant GliomaTerminatedNCT00430079Not applicable
• Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LymphomaCompletedNCT00363272Phase 1
• ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant GliomaCompletedNCT00352313Phase 1/2
• A Family Study of Adults With GliomaCompletedNCT00339352
• AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS TumorsCompletedNCT00326664Phase 1
• Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation NecrosisCompletedNCT00285324
• ZD6474 to Treat Advanced Brain Cancer in PatientsCompletedNCT00272350Phase 1
• Vorinostat and Temozolomide in Treating Patients With Malignant GliomasActive, not recruitingNCT00268385Phase 1
• Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain TumorsTerminatedNCT00110032Phase 1
• Enzastaurin to Treat Recurrent Brain TumorTerminatedNCT00108056Phase 1
• GW572016 to Treat Recurrent Malignant Brain TumorsCompletedNCT00107003Phase 2
• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasCompletedNCT00101270Phase 1
• Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS TumorsCompletedNCT00100880Phase 1
• Sorafenib in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00093613Phase 1
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00091182Phase 2
• Alanosine in Treating Patients With Progressive or Recurrent Malignant GliomasCompletedNCT00075894Phase 1
• CC-8490 in Treating Patients With Recurrent or Refractory High-Grade GliomasCompletedNCT00074243Phase 1